Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ)
Background. Current clinical guidelines on diagnosis and treatment of chronic myeloid leukemia (CML) define indications for substitution of first-line tyrosine kinase inhibitor (TKI) at therapy failure during different phases of disease progression. Aim. To assess the efficacy of CML treatment with...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2019-03-01
|
| Series: | Клиническая онкогематология |
| Subjects: | |
| Online Access: |
http://bloodjournal.ru/wp-content/uploads/2019/03/10.pdf
|
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849685955228729344 |
|---|---|
| author | OA Shukhovv AG Turkina EYu Chelysheva AV Bykova AN Petrova GA Gusarova IS Nemchenko AO Abdullaev TN Obukhova AB Sudarikov |
| author_facet | OA Shukhovv AG Turkina EYu Chelysheva AV Bykova AN Petrova GA Gusarova IS Nemchenko AO Abdullaev TN Obukhova AB Sudarikov |
| author_sort | OA Shukhovv |
| collection | DOAJ |
| description | Background. Current clinical guidelines on diagnosis and treatment of chronic myeloid leukemia (CML) define indications for substitution of first-line tyrosine kinase inhibitor (TKI) at therapy failure during different phases of disease progression.
Aim. To assess the efficacy of CML treatment with implementing the protocol of timely monitoring and switching to another TKI.
Materials & Methods. Patients were included into pilot prospective study РИТМ during 5 years. Data on 100 CML patients were analyzed. Therapy and monitoring were conducted according to the Federal clinical guidelines on CML diagnosis and therapy, 2013.
Results. Median follow-up after initiation of treatment was 46 months (range 12–74). Imatinib mesylate was administered as first-line therapy to 91 (91 %) patients, 9 (9 %) patients received 2nd generation TKI (TKI2). Therapy failure was registered in 31 (31 %) patients; 26 (84 %) of them were switched to TKI2. At the time of analysis 95 (95 %) patients were followed-up. Cumulative incidence of CML-associated mortality was 2 %. By the fifth year of follow-up cumulative probability of complete cytogenetic, major and deep molecular responses was 93 %, 88 % and 66 %, respectively.
Conclusion. CML treatment according to current guidelines yields the results comparable with those achieved by first-line TKI2 therapy. This approach reduces CML treatment costs and lowers the risk of TKI2-associated adverse events. Due to a high rate of deep molecular response the proportion of CML patients in remission without treatment can be increased in the future. |
| format | Article |
| id | doaj-art-bac79a6b62dd44bf835ec54dd79a3b9f |
| institution | DOAJ |
| issn | 1997-6933 2500-2139 |
| language | Russian |
| publishDate | 2019-03-01 |
| publisher | Practical Medicine Publishing House |
| record_format | Article |
| series | Клиническая онкогематология |
| spelling | doaj-art-bac79a6b62dd44bf835ec54dd79a3b9f2025-08-20T03:22:53ZrusPractical Medicine Publishing HouseКлиническая онкогематология1997-69332500-21392019-03-0112219420110.21320/2500-2139-2019-12-2-194-20119976933Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ)OA Shukhovv0AG Turkina1EYu Chelysheva2AV Bykova3AN Petrova4GA Gusarova5IS Nemchenko6AO Abdullaev7TN Obukhova8AB Sudarikov9 National Medical Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 National Medical Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 National Medical Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 National Medical Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 National Medical Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 National Medical Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 National Medical Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 National Medical Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 National Medical Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 National Medical Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 Background. Current clinical guidelines on diagnosis and treatment of chronic myeloid leukemia (CML) define indications for substitution of first-line tyrosine kinase inhibitor (TKI) at therapy failure during different phases of disease progression. Aim. To assess the efficacy of CML treatment with implementing the protocol of timely monitoring and switching to another TKI. Materials & Methods. Patients were included into pilot prospective study РИТМ during 5 years. Data on 100 CML patients were analyzed. Therapy and monitoring were conducted according to the Federal clinical guidelines on CML diagnosis and therapy, 2013. Results. Median follow-up after initiation of treatment was 46 months (range 12–74). Imatinib mesylate was administered as first-line therapy to 91 (91 %) patients, 9 (9 %) patients received 2nd generation TKI (TKI2). Therapy failure was registered in 31 (31 %) patients; 26 (84 %) of them were switched to TKI2. At the time of analysis 95 (95 %) patients were followed-up. Cumulative incidence of CML-associated mortality was 2 %. By the fifth year of follow-up cumulative probability of complete cytogenetic, major and deep molecular responses was 93 %, 88 % and 66 %, respectively. Conclusion. CML treatment according to current guidelines yields the results comparable with those achieved by first-line TKI2 therapy. This approach reduces CML treatment costs and lowers the risk of TKI2-associated adverse events. Due to a high rate of deep molecular response the proportion of CML patients in remission without treatment can be increased in the future. http://bloodjournal.ru/wp-content/uploads/2019/03/10.pdf chronic myeloid leukemiamonitoringtyrosine kinase inhibitorstki switch |
| spellingShingle | OA Shukhovv AG Turkina EYu Chelysheva AV Bykova AN Petrova GA Gusarova IS Nemchenko AO Abdullaev TN Obukhova AB Sudarikov Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ) Клиническая онкогематология chronic myeloid leukemia monitoring tyrosine kinase inhibitors tki switch |
| title | Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ) |
| title_full | Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ) |
| title_fullStr | Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ) |
| title_full_unstemmed | Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ) |
| title_short | Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ) |
| title_sort | treatment of chronic myeloid leukemia according to current guidelines the results of the pilot prospective study early induction therapy and monitoring ритм |
| topic | chronic myeloid leukemia monitoring tyrosine kinase inhibitors tki switch |
| url |
http://bloodjournal.ru/wp-content/uploads/2019/03/10.pdf
|
| work_keys_str_mv | AT oashukhovv treatmentofchronicmyeloidleukemiaaccordingtocurrentguidelinestheresultsofthepilotprospectivestudyearlyinductiontherapyandmonitoringritm AT agturkina treatmentofchronicmyeloidleukemiaaccordingtocurrentguidelinestheresultsofthepilotprospectivestudyearlyinductiontherapyandmonitoringritm AT eyuchelysheva treatmentofchronicmyeloidleukemiaaccordingtocurrentguidelinestheresultsofthepilotprospectivestudyearlyinductiontherapyandmonitoringritm AT avbykova treatmentofchronicmyeloidleukemiaaccordingtocurrentguidelinestheresultsofthepilotprospectivestudyearlyinductiontherapyandmonitoringritm AT anpetrova treatmentofchronicmyeloidleukemiaaccordingtocurrentguidelinestheresultsofthepilotprospectivestudyearlyinductiontherapyandmonitoringritm AT gagusarova treatmentofchronicmyeloidleukemiaaccordingtocurrentguidelinestheresultsofthepilotprospectivestudyearlyinductiontherapyandmonitoringritm AT isnemchenko treatmentofchronicmyeloidleukemiaaccordingtocurrentguidelinestheresultsofthepilotprospectivestudyearlyinductiontherapyandmonitoringritm AT aoabdullaev treatmentofchronicmyeloidleukemiaaccordingtocurrentguidelinestheresultsofthepilotprospectivestudyearlyinductiontherapyandmonitoringritm AT tnobukhova treatmentofchronicmyeloidleukemiaaccordingtocurrentguidelinestheresultsofthepilotprospectivestudyearlyinductiontherapyandmonitoringritm AT absudarikov treatmentofchronicmyeloidleukemiaaccordingtocurrentguidelinestheresultsofthepilotprospectivestudyearlyinductiontherapyandmonitoringritm |